智通财经APP获悉，四环医药(00460)早盘涨超12%，截至发稿，涨8.33%，报0.91港元，成交额5161.24万港元。
消息面上，近日，由四环医药渼颜空间牵头，携手全国多家公立医院与头部医美机构共同完成的冻妍临床研究，取得重要学术成果。相关研究论文正式发表于皮肤科领域国际权威SCI期刊《Journal of Cosmetic Dermatology》。这一成果不仅为冻妍（国内首款含L-肌肽的合规面部动能素）注入了高质量的临床循证证据，更标志着其在提升皮肤质量方面的疗效获得国际学术界的高度认可。
中信建投此前指出，展望2026年：作为核心增长引擎，核心大单品乐提葆销量有望进一步提升，同时25H2上市的童颜针、少女针、动能素等再生及水光类新品将迎来首个完整销售年，有望通过组合销售带动新品快速放量；在此基础上，随着公司产品矩阵持续完善及渠道规模化效应，有望驱动医美板块盈利能力持续提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.